The incidence of type I galactosemia is around 1 in every 60,000 newborns, while type II affects fewer than 1 in 100,000 newborns and type III affects fewer still. When an infant with galactosemia ...

One of the enzymes involved is galactose-1-phosphate uridyl transferase (GALT) and in galactosemia, this enzyme is either defective or missing. When this happens, an infant is unable to convert ...

In the phase III ACTION-Galactosemia Kids study in children with ... Allogene Therapeutics’ estimates for loss per share have ...

Concretely, galactosemia is a rare genetic disorder caused by a lack of the enzyme galactose-1-phosphate uridylyltransferase [GALT] for metabolizing galactose, a sugar component of lactose present ...

A deficiency in the enzyme galactose-1-phosphate uridylyl transferase (GALT ... In the Phase III registrational ACTION-Galactosemia Kids study (NCT04902781) in children with galactosemia between ...

Galactosemia is a rare genetic, metabolic disorder caused by a deficiency in the galactose-1-phosphate uridyltransferase (GALT). This means patients cannot break down galactose, causing a buildup ...

The NDA for govorestat for the galactosemia indication was accepted ... estimates for Illumina’s 2024 EPS have moved up from $1.84 to $3.63. The consensus estimate for 2025 earnings has improved ...

The NDA included data from the phase 1/2 ACTION-Galactosemia study (ClinicalTrial.gov Identifier: NCT04117711) and the phase 3 ACTION-Galactosemia Kids trial (ClinicalTrial.gov Identifier ...

We expect 2030 sales of govorestat to exceed $1 billion with 70% peak penetration in the galactosemia market. With a global patient population of ~7k patients - although only ~3k of these are ...

It’s easy to test for galactosemia. It’s also simple to treat once it’s diagnosed. And children who have it can live normal lives. Type I occurs in about 1 in every 30,000 to 60,000 people.